CoChat

New-Generation Antidepressants, Suicide and Depressed Adolescents: How Should Clinicians Respond to Changing Evidence?

Dudley, Michael, Hadzi-Pavlovic, Dusan, Andrews, Doug, Perich, Tania · 2008 · Australian & New Zealand Journal of Psychiatry

The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.

Abstract

The purpose of the present paper was to identify, from the voluminous literature on efficacy and safety in new-generation antidepressants (NGAs) with depressed children and adolescents, practical clinical strategies for acute phase treatment. To this end a pragmatic survey of studies and reviews was undertaken. Meta-analyses of randomized controlled trials of NGAs in depressed children and adolescents have noted a comparative lack of efficacy, and a weak but statistically significant increased risk of self-harm and suicidal thoughts. But NGA prescription rates and youth suicide rates are generally inversely related, and ensuing ‘black box’ warnings about NGAs, by deterring NGA prescribing, have possibly contributed to rising youth suicide rates. In moderate–severe depression, benefits for fluoxetine and possibly other NGAs demonstrably outweigh risks. NGAs are not present in adolescents who die by suicide. Concern about NGA risks must be balanced against risks of non-treatment. While mild depression entails regular review, psychoeducation, self-care strategies and psychological interventions, NGAs should be administered concurrently with psychological treatments if depression is moderate– to severe, or if mild depression persists. Patients should be warned about off-label status of NGAs in depression, serious side-effects such as ‘activation’, suicidality, emotional blunting and manic switches, the need for adherence and avoiding abrupt discontinuation. They should be monitored early and regularly. Better evidence is required regarding psychological treatments, clinical course, and clinical practice trends. In moderate–severe depression the risk of suicide if NGAs are not used may outweigh any risk of self-harm associated with them.

Overview

Integrity signals

Registry

Crossref · 10.1080/00048670802050538

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 99 references

Research works printed but not linked: 21

  1. Hammad T, Results of the analysis of suicidality in pediatric trials of newer antidepressants
  2. Leon A, 1993, J Clin Psychiatry; 65, 2004, 915
  3. 10.1080/j.1440-1614.2006.01812.x · doi:10.1080/j.1440-1614.2006.01812.x
  4. 10.1080/j.1440-1614.2000.00691.x · doi:10.1080/j.1440-1614.2000.00691.x · Paper page
  5. Kirsch D, 2004, FDA testimony of Dr David Kirsch and Dr David Antonuccio on the efficacy of antidepressants in children
  6. Rothschild AJ, 1991, J Clin Psychiatry, 52, 491
  7. Teicher MH, 1990, Am J Psychiatry, 142, 207
  8. Department of Health and Human Services PHS, Food and Drug Administration, 1991, Psychopharmacological Drugs Advisory Committee
  9. European Medicines Agency, 2005, European Medicines Agency finalises review of antidepressants in children and adolescents
  10. Australian Adverse Drug Reactions Advisory Committee, 2004, Use of SSRI antidepressants in children and adolescents
  11. Breggin PR, 2004, Int J Risk Saf Med, 16, 31
  12. US Food and Drug Administration Clinical Review, 2006, Relationship between antidepressant drugs and suicidality in adults
  13. Mackay F, 1999, Br J Gen Pract, 49, 892
  14. Bell G, 2005, Q Essay, 18, 1
  15. Parker G, 2005, Q Essay, 19, 88
  16. Committee of Safety of Medicines, 2005, Selective serotonin reuptake inhibitors (SSRIs): overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents
  17. Shaffer D, 2005, Comprehensive textbook of psychiatry, vol II, 3262
  18. Rigioni GC, Drug utilization for selected antidepressants among children & adolescents in the US
  19. Mayer-Gross W, 1960, Clinical psychiatry
  20. Royal Australian and New Zealand College of Psychiatrists, Royal College of General Practitioners, and Royal Australasian College of Physicians, 2005, Aust Fam Physician, 34, 777
  21. 2003, Therapeutic Guidelines: Psychotropic

Cited by

See all 15

Metadata

Authors
Dudley, M., Hadzi-Pavlovic, D., Andrews, D., & Perich, T.
Affiliations
  • UNSW Sydney (AU)
  • Black Dog Institute, and School of Psychiatry, University of New South Wales, Randwick, New South Wales, Australia
  • Black Dog Institute (AU)
Corresponding author
Dudley, Michael
Venue
Australian & New Zealand Journal of Psychiatry
Published
2008-01-01
Volume
42
Issue
6
Pages
456-466
ISSN
  • 0004-8674 (ISSN-L)
  • 1440-1614
OpenAlex
W2147818745
Cited by
15
References
99
Citations by year
2024: 1 · 2023: 1 · 2021: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2014: 2 · 2013: 1 · 2012: 1
FWCI
0.18
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Australian & New Zealand Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Health and Medical Research Council
  • National Institute of Mental Health
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
Keywords
adolescent depression, youth suicide, suicidality, fluoxetine, black box warning, antidepressant prescribing, treatment-resistant depression, off-label drug use, emotional blunting, manic switch, medication adherence, suicide prevention, psychoeducation
MeSH terms
Suicide Prevention, Adolescent, Child, Depressive Disorder, Humans, Suicide, Meta-Analysis as Topic, Treatment Outcome, Practice Guidelines as Topic, Risk Assessment, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New-Generation Antidepressants, Suicide and Depressed Adolescents: How Should Clinicians Respond to Changing Evidence? https://app.cochat.ai/papers/10.1080/00048670802050538
The paper
Dudley, M., Hadzi-Pavlovic, D., Andrews, D., & Perich, T. (2008). New-Generation Antidepressants, Suicide and Depressed Adolescents: How Should Clinicians Respond to Changing Evidence? Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1080/00048670802050538

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.